Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
AssigneesCrucell Holland B.V., Beth Israel Deaconess Medical Center, Inc.
InventorsMenzo Jans Emko Havenga, Dan H. Barouch
Life of this patent
Estimating the term…
Abstract
The present application relates to recombinant adenoviruses, more in particular those that encounter low levels of pre-existing neutralizing activity in hosts that are in need of treatment or vaccination. Particularly, the invention relates to recombinant vectors derived from two subgroup D adenoviruses: Ad26 and Ad48.
Claims40
An isolated nucleic acid having at least 90% sequence identity to the sequence set forth in SEQ ID NO:1, wherein said nucleic acid comprises structural and non-structural elements of an adenovirus serotype 26 (Ad26).
An isolated nucleic acid having at least 90% sequence identity to the sequence set forth in SEQ ID NO:2, wherein said nucleic acid comprises structural and non-structural elements of an adenovirus serotype 48 (Ad48).
Dependencies are inferred from the claim text.